By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Novartis
Pharmaceuticals Corp. et al. v. Noven
Pharmaceuticals Inc. et al.
1:13-cv-00527;
filed April 3, 2013 in the District Court of Delaware

• Plaintiffs: 
Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis
International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: 
Noven Pharmaceuticals Inc.; Noven Therapeutics LLC; Hisamitsu Pharmaceutical
Co. Inc.

Infringement
of U.S. Patent Nos. 6,316,023 ("TTS Containing an Antioxidant,"
issued November 13, 2001) and 6,335,031 (same title, issued January 1, 2002)
following a Paragraph IV certification as part of Noven's filing of an ANDA to
manufacture a generic version of Novartis' Exelon® Patch (rivastigmine
tartrate, used to treat mild to moderate dementia of the Alzheimer's type, and
mild to moderate dementia associated with Parkinson's disease).  View the complaint here.

Purdue
Pharmaceutical Products L.P. et al. v. Dr. Reddy's Laboratories, Inc. et al.
2:13-cv-02067;
filed April 2, 2013 in the District Court of New Jersey

• Plaintiffs: 
Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Transcept
Pharmaceuticals, Inc.
• Defendants: 
Dr. Reddy's Laboratories, Inc.; Dr. Reddys Laboratories, Ltd.

Infringement
of U.S. Patent Nos. 7,682,628 ("Compositions for Delivering Hypnotic
Agents Across the Oral Mucosa and Methods of Use Thereof," issued March
23, 2010), 8,242,131 ("Methods of Treating Middle-of-the-Night Insomnia,"
issued August 14, 2012), and 8,252,809 ("Compositions for Treating Insomnia,"
issued August 28, 2012) following a Paragraph IV certification as part of Dr.
Reddy's filing of an ANDA to manufacture a generic version of Purdue's
Intermezzo® (sublingual zolpidem tartrate, used to treat insomnia when
middle-of-the-night awakening is followed by difficulty returning to
sleep).  View the complaint here.

Taro
Pharmaceuticals North America, Inc. v. Rea
1:13-cv-00410;
filed April 1, 2013 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,277,780 ("Stable Liquid
Desoximethasone Compositions with Reduced Oxidized Impurity," issued
October 2, 2012).  View the complaint here.

Incyte
Corp. v. Rea
1:13-cv-00409;
filed March 29, 2013 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,278,318 ("Spriocycles and
Inhibitors of 11-Beta Hydroxyl Steroid Dehydrogenase Type 1," issued
October 2, 2012).  View the complaint here.

Unimed
Pharmaceuticals LLC et al. v. Watson Laboratories Inc. et al.
1:13-cv-00496;
filed March 29, 2013 in the District Court of Delaware

• Plaintiffs: 
Unimed Pharmaceuticals LLC; Besins Healthcare Inc.
• Defendants: 
Watson Laboratories Inc.; Actavis Inc.

Infringement
of U.S. Patent No. 6,503,894 ("Pharmaceutical Composition and Method for
Treating Hypogonadism," issued January 7, 2003) following a Paragraph IV
certification as part of Watson's filing of an ANDA to manufacture a generic
version of AbbVie's AndroGel® (testosterone gel, used to treat conditions
associated with a deficiency or absence of endogenous testosterone).  View the complaint here.

Takeda
Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC
1:13-cv-00493;
filed March 28, 2013 in the District Court of Delaware

Infringement
of U.S Patent Nos. 7,619,004 ("Methods for Concomitant Administration of
Colchicine and Macrolide Antibiotics," issued November 17, 2009),
7,601,758 ("Methods for Concomitant Administration of Colchicine and
Macrolide Antibiotics in the Treatment of Gout Flares," issued October 13,
2009), 7,820,681 ("Methods for Concomitant Administration of Colchicine
and a Second Active Agent," issued October 26, 2010), 7,915,269 (same
title, issued March 29, 2011), 7,964,647 ("Colchicine Compositions and
Methods," issued June 21, 2011), 7,964,648 ("Methods for Concomitant
Administration of Colchicine and a Second Active Agent," issued June 21,
2011), 7,981,938 ("Colchicine Compositions and Methods," issued July
19, 2011), 8,093,296 ("Methods for Concomitant Administration of
Colchicine and Macrolide Antibiotics," issued January 10, 2012), 8,093,297
("Methods for Concomitant Administration of Colchicine and a Second Active
Agent," issued January 10, 2012), and 8,097,655 ("Methods for
Concomitant Administration of Colchicine and Macrolide Antibiotics,"
issued January 17, 2012) following Amneal's filing of an ANDA to manufacture a
generic version of Takeda's Colcrys® (single-ingredient colchicine product,
used to prevent and treat gout flares). 
View the complaint here.

Mallinckrodt
LLC et al. v. Taro Pharmaceutical Industries Ltd. et al.
1:13-cv-00494;
filed March 28, 2013 in the District Court of Delaware

• Plaintiffs: 
Mallinckrodt LLC; Mallinckrodt Inc.; Nuvo Research Inc.
• Defendants: 
Taro Pharmaceutical Industries Ltd.; Taro Pharmaceutical USA Inc.

Infringement
of U.S. Patent No. 8,217,078 ("Treatment of Pain with Topical Diclofenac,"
issued July 10, 2012) following a Paragraph IV certification as part of Taro's
filing of an ANDA to manufacture a generic version of Mallinckrodt's Pennsaid®
(diclofenac sodium topical solution, used for the treatment of signs and
symptoms of osteoarthritis of the knee(s)). 
View the complaint here.